HawkOne directional atherectomy system

The DIRECT Trial results

The randomized DIRECT Trial1 demonstrated that lesions treated with the HawkOne™ directional atherectomy system had greater plaque volume reduction and luminal gain — with similar safety profiles — than those treated with the CSI Diamondback 360®* peripheral orbital atherectomy system. Results confirmed through IVUS and angiography.

HawkOne directional atherectomy system

Percent stenosis by angiography

There was a greater reduction in stenosis following directional atherectomy (DA) compared to orbital atherectomy (OA).

Chart of the DIRECT trial stenosis pretreatment rate, which includes the HawkOne directional atherectomy rate

Pretreatment

DA: 90.7% | OA: 87.3%
(p = 0.48)

Chart of the DIRECT trial stenosis post-atherectomy rate, which includes the HawkOne directional atherectomy rate

Post-atherectomy

DA: 39.5% | OA: 69.8%
(p < 0.001)

Chart of the DIRECT trial stenosis post-drug-coated balloon rate, which includes the HawkOne directional atherectomy rate

Post-DCB

DA: 16.7% | OA: 33.7%
(p < 0.001)

Representative case examples

Directional atherectomy — IVUS area stenosis

DIRECT trial pretreatment angiogram using directional atherectomy

Pretreatment

69.2%

DIRECT trial post-atherectomy angiogram using directional atherectomy

Post-atherectomy

54.1%

DIRECT trial post-DCB angiogram using directional atherectomy

Post-DCB

5.6%

Intravascular ultrasound (IVUS) results of directional atherectomy

Mechanism of lumen enlargement: plaque reduction and vessel stretch

Orbital atherectomy — IVUS area stenosis

DIRECT trial pretreatment angiogram using orbital atherectomy

Pretreatment

84.2%

DIRECT trial post-atherectomy angiogram using orbital atherectomy

Post-atherectomy

74.8%

DIRECT trial post-DCB angiogram using orbital atherectomy

Post-DCB

59.8%

Intravascular ultrasound (IVUS) results of orbital atherectomy

Mechanism of lumen enlargement: medial dissection and vessel stretch

Plaque volume

Greater plaque volume reduction was achieved with directional atherectomy group compared to orbital atherectomy group. This difference in plaque volume reduction persisted following drug-coated balloon (DCB) utilization.

Plaque volume (worst 10 mm segment)

Chart of the DIRECT trial plaque pretreatment rate, which includes the HawkOne directional atherectomy rate

Pretreatment

DA: 81.8% | OA: 82.2%
(p = 0.8)

Chart of the DIRECT trial plaque post-atherectomy rate, which includes the HawkOne directional atherectomy rate

Post-atherectomy

DA: 66.5% | OA: 75.6%
(p = 0.0002)

Chart of the DIRECT trial plaque post-drug-coated balloon rate, which includes the HawkOne directional atherectomy rate

Post-DCB

DA: 54.5% | OA: 61.3%
(p = 0.003)

Plaque volume (entire lesion)

Chart of the DIRECT trial plaque volume plaque pretreatment rate, which includes the HawkOne directional atherectomy rate

Pretreatment

DA: 68.3% | OA: 69.0%
(p = 0.43)

Chart of the DIRECT trial plaque volume plaque post-atherectomy rate, which includes the HawkOne directional atherectomy rate

Post-atherectomy

DA: 61.4% | OA: 67.0%
(p = 0.06)

Chart of DIRECT trial plaque volume plaque post-drug-coated balloon rate, which includes HawkOne directional atherectomy rate

Post-DCB

DA: 53.2% | OA: 56.7%
(p = 0.01)

Stent placement rate

  • HawkOne directional atherectomy (DA): 7% (2/30)
  • Diamondback 360 orbital atherectomy (OA): 33% (10/30)

Chart of the DIRECT trial stent placement rate, including the HawkOne directional atherectomy rate

(p = 0.02)

Safety events and complications

Overall directional and orbital atherectomy were found to be safe with minimal complications.

Directional atherectomy (n = 30)

  • Perforations: 1 (3%)
  • Distal embolic protection device used: 29 (97%)
  • Distal embolization post-DCB: 0 (0%)

Orbital atherectomy (n = 30)

  • Perforations: 0 (0%)
  • Distal embolic protection device used: 28 (93%)
  • Distal embolization post-DCB: 1 (3%)

Results may not be indicative of clinical performance, and are dependent on experience and training. The DIRECT study was an investigator-initiated study supported by an institutional grant from Medtronic. Three-year follow-up is ongoing to determine whether these acute performance measures are associated with improved clinical outcomes.

Risks may include but are not limited to: arterial perforation, embolism or arterial thrombosis, arterial dissection, arterial spasm, and vascular complications that could require surgical repair.

HawkOne directional atherectomy system

HawkOne directional atherectomy system

From simple to complex cases, the HawkOne directional atherectomy system offers the versatility and efficiency physicians need to remove plaque and restore flow.

Download

pdf DIRECT study results (.pdf)

Download this clinical paper review to learn more about DIRECT study results.

183KB

*

™Third-party brands are trademarks of their respective owners.

Values are expressed as median (interquartile range).

Reference

1

Babaev A, Halista M, Bakirova Z, et al. Directional versus orbital atherectomy of femoropopliteal artery lesions: Angiographic and intravascular ultrasound outcomes. Catheter Cardiovasc Interv. October 2022;100(4);687–695.